HERMES: A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation
Sponsor
Novo Nordisk A/S (Industry)
Overall Status
Not yet recruiting
CT.gov ID
NCT05636176
Collaborator
(none)
5,600
421
2
49.8
13.3
0.3
Study Details
Study Description
Brief Summary
This study will be done to see if ziltivekimab can be used to treat people living with heart failure and inflammation. Participants will either get ziltivekimab or placebo. The study is expected to last for up to 4 years. Participants will have up to 20 clinic visits. Participants will have to use a study app on their phone to record and share information about all their injections of study medicine and to fill in questionnaires.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 3 |
Study Design
Study Type:
Interventional
Anticipated Enrollment
:
5600 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
HERMES: Effects of Ziltivekimab Versus Placebo on Morbidity and Mortality in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction and Systemic Inflammation
Anticipated Study Start Date
:
May 8, 2023
Anticipated Primary Completion Date
:
Jul 2, 2027
Anticipated Study Completion Date
:
Jul 2, 2027
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Ziltivekimab 15 mg Participants will receive ziltivekimab 15 milligrams (mg) subcutaneous (s.c.) injection once-monthly and added to standard of care for up to 4 years. |
Drug: Ziltivekimab
Participants will receive ziltivekimab 15 milligrams (mg) subcutaneous (s.c.) injection once-monthly and added to standard of care for up to 4 years.
|
| Placebo Comparator: Placebo Participants will receive ziltivekimab placebo subcutaneous (s.c.) injection once-monthly and added to standard of care for up to 4 years. |
Drug: Placebo
Participants will receive ziltivekimab placebo subcutaneous (s.c.) injection once-monthly and added to standard of care for up to 4 years.
|
Outcome Measures
Primary Outcome Measures
- Time to First Occurrence of a Composite Heart Failure Endpoint Consisting of: Cardiovascular (CV) Death, Heart Failure (HF) Hospitalisation or Urgent HF Visit [From randomisation (month 0) to end of study (up to 48 months)]
Measured in months.
Secondary Outcome Measures
- Time to First Occurrence of 4-point Expanded Composite HF Endpoint, a Composite Endpoint Consisting of: CV Death, HF Hospitalisation or Urgent HF Visit, Non-fatal Myocardial Infarction (MI), Non-fatal Stroke [From randomisation (month 0) to end of study (up to 48 months)]
Measured in months.
- Number of CV Deaths, HF Hospitalisations or Urgent HF Visits (First and Recurrent) [From randomisation (month 0) to end of study (up to 48 months)]
Measured as count of event.
- Time to Occurrence of CV Death [From randomisation (month 0) to end of study (up to 48 months)]
Measured in months.
- Time to Occurrence of all-cause Death [From randomisation (month 0) to end of study (up to 48 months)]
Measured in months.
- Time to First Occurrence of 4-point Expanded Composite HF Endpoint, a Composite Endpoint Consisting of: All-cause Death, HF Hospitalisation or Urgent HF Visit, Non-fatal MI, Non-fatal stroke [From randomisation (month 0) to end of study (up to 48 months)]
Measured in months.
- Hierarchical Composite of: Time to All-cause Death, Number of HF Hospitalisations or Urgent HF Visits, Time to First HF Hospitalisation or Urgent HF Visit, difference of at least 5 in KCCQ clinical summary score change from baseline to 12 months [From randomisation (month 0) to end of study (up to 48 months)]
Kansas City Cardiomyopathy Questionnaire (KCCQ) measures Health-Related Quality of Life (HRQOL) and is a disease-specific health status instrument for HF. Score ranges from 0 to 100, with 0 as the lowest score and 100 as the highest score. Higher scores indicate better health status, fewer symptoms, and greater disease-specific health related quality of life, respectively. Measured as total wins for each treatment group.
- Time to First Occurrence of HF Hospitalisation or Urgent HF Visit [From randomisation (month 0) to end of study (up to 48 months)]
Measured in months.
- Number of Events of Atrial Fibrillation [From randomisation (month 0) to end of study (up to 48 months)]
Measured as count of event.
- Change in KCCQ Clinical Summary Score [From randomisation (month 0) to 12 months]
KCCQ measures Health-Related Quality of Life (HRQOL) and is a disease-specific health status instrument for HF. Score ranges from 0 to 100, with 0 as the lowest score and 100 as the highest score. Higher scores indicate better health status, fewer symptoms, and greater disease-specific health related quality of life, respectively. Measured as score.
- Improvement of 5 Points or More in KCCQ Clinical Summary Score (Yes/No) [From randomisation (month 0) to 12 months]
Kansas City Cardiomyopathy Questionnaire (KCCQ) measures Health-Related Quality of Life (HRQOL) and is a disease-specific health status instrument for HF. Score ranges from 0 to 100, with 0 as the lowest score and 100 as the highest score. Higher scores indicate better health status, fewer symptoms, and greater disease-specific health related quality of life, respectively. Measured as count of participant.
- Improvement of 10 Points or More in KCCQ Clinical Summary Score (Yes/No) [From randomisation (month 0) to 12 months]
Kansas City Cardiomyopathy Questionnaire (KCCQ) measures Health-Related Quality of Life (HRQOL) and is a disease-specific health status instrument for HF. Score ranges from 0 to 100, with 0 as the lowest score and 100 as the highest score. Higher scores indicate better health status, fewer symptoms, and greater disease-specific health related quality of life, respectively. Measured as count of participant.
- Improvement in New York Heart Association (Classification) [NYHA Class] (Yes/No) [From randomisation (month 0) to 12 months]
NEW YORK HEART ASSOCIATION CLASSIFICATION (NYHA) Class I: Participant with cardiac disease but without resulting limitations of physical activity. Class II: Participants with cardiac disease resulting in slight limitation of physical activity. Class III: Participants with cardiac disease resulting in marked limitation of physical activity. Class IV: Participants with cardiac disease resulting in inability to carry on any physical activity without discomfort. Measured as count of participant.
- Time to First Occurrence of a Composite Chronic Kidney Disease (CKD) Endpoint Consisting of: CV death, Onset of Persistent Greater Than Equal To 40 Percentage Reduction in eGFR (CKD- EPI) compared with baseline; Kidney failure [From randomisation (month 0) to end of study (up to 48 months)]
eGFR = estimated glomerular filtration rate; CKD-EPI = chronic kidney disease - epidemiology collaboration. Kidney failure defined as: death from kidney failure, onset of persistent eGFR less than 15 milliliters per minute (mL/min)/1.73 meter square (m^2) (CKD-EPI), initiation of chronic kidney replacement therapy (maintenance dialysis or kidney transplantation). Measured in months.
- Change in Estimated Glomerular Filtration Rate (eGFR) (Chronic Kidney Disease - Epidemiology Collaboration [CKD-EPI]) [From randomisation (month 0) to 12 months]
Measured as mL/min/1.73 m^2.
- Annual Rate of Change in eGFR (CKD-EPI) (Total eGFR Slope) [From randomisation (month 0) to end of study (up to 48 months)]
Measured as mL/min/1.73 m^2/year.
- Number of Hospitalisations With Infection as Primary Cause or Death Due to Infection [From randomisation (month 0) to end of study (up to 48 months)]
Measured as count of event.
- Change in High-sensitivity C-reactive Protein (hs-CRP) [From randomisation (month 0) to 12 months]
Measured as ratio to baseline.
- Change in N-terminal-pro-brain Natriuretic Peptide (NT-proBNP) [From randomisation (month 0) to 12 months]
Measured as ratio to baseline.
Eligibility Criteria
Criteria
Ages Eligible for Study:
18 Years
and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
-
Serum high-sensitivity C-reactive protein (hs-CRP) greater than equal to 2 milligrams per liter (mg/L) at screening (visit 1) Disease specific - cardiovascular
-
At least one of the following:
-
N-terminal-pro-brain natriuretic peptide (NT-proBNP) greater than equal to 300 picograms per milliliter (pg/mL) at screening (Visit 1) for patients without ongoing atrial fibrillation/flutter. If ongoing atrial fibrillation/flutter at screening (visit 1), NTproBNP must be greater than equal to 600 pg/mL.
-
Hospitalisation or urgent/unplanned visit with a primary diagnosis of decompensated heart failure which required intravenous loop diuretic treatment, within the last 9 months prior to screening (visit 1) in combination with NT-proBNP greater than equal to 200 pg/mL at screening (Visit 1) for patients without ongoing atrial fibrillation/flutter. If ongoing atrial fibrillation/flutter at screening (visit 1), NT-proBNP must be greater than equal to 600 pg/mL.
-
Diagnosis of heart failure (New York Heart Association [classification] [NYHA] Class II-IV).
-
Left ventricular ejection fraction (LVEF) greater than 40 percentage (%) documented by echocardiography within 12 months prior to or at screening (visit 1). The LVEF must be documented in medical records and the most recent measurement must be used to determine eligibility with no interim event signalling potential deterioration in ejection fraction (e.g., myocardial infarction [MI] or heart failure [HF] hospitalisation).
-
Structural heart disease and/or functional heart disease documented by echocardiography within 12 months prior to or at screening (visit 1) showing at least one of the following:
-
Left atrial (LA) volume index greater than 34 milliliter per meter square (mL/m^2).
-
LA diameter greater than equal to 3.8 centimeter (cm).
-
LA length greater than equal to 5.0 cm.
-
LA area greater than equal to 20 cm square.
-
LA volume greater than equal to 55 milliters (mL).
-
Intraventricular septal thickness greater than equal to 1.1 cm.
-
Posterior wall thickness greater than equal to 1.1 cm.
-
Left ventricular (LV) mass index greater than equal to 115 grams per meter square (g⁄m2 ) in men or greater than equal to 95 g⁄m2 in women.
-
E/e' (mean septal and lateral) greater than equal to 10.
-
e' (mean septal and lateral) less than 9 centimeter per second (cm/s).
-
No heart failure hospitalisations or urgent heart failure visits between screening (visit 1) and randomisation (visit 2).
Exclusion Criteria:
Medical conditions - cardiovascular
-
Myocardial infarction, stroke, unstable angina pectoris, transient ischaemic attack, or heart failure hospitalisation, within 30 days prior to screening (visit 1).
-
Systolic blood pressure greater than equal to 180 millimeters of mercury (mmHg) at screening (visit 1). If the systolic blood pressure is 160-179 mmHg, the patient should be receiving greater than equal to 3 antihypertensive drugs. (Note: Potential participants may be retested for this criterion within the visit window and without rescreening, at the discretion of the investigator).
-
Heart rate above 110 or below 40 beats per minute as evaluated on the electrocardiogram (ECG) performed at screening (visit 1) (Note: Potential participants may be retested for this criterion within the visit window and without rescreening, at the discretion of the investigator).
-
Planned coronary, carotid or peripheral artery revascularisation known during the screening period (visit 1). (Note: Planned coronary angiogram is not exclusionary).
-
Planned cardiac device or atrial flutter/atrial fibrillation ablation procedure known during the screening period (visit 1).
-
Major cardiac surgical, non-cardiac surgical, or major endoscopic procedure (thoracoscopic or laparoscopic) within the past 60 days prior to randomisation (visit
- or any major surgical procedure planned at the time of randomisation (visit 2).
-
Heart failure due to infiltrative cardiomyopathy (e.g., sarcoid, amyloid), arrhythmogenic right ventricular cardiomyopathy, Takutsubo cardiomyopathy, genetic hypertrophic cardiomyopathy or obstructive cardiomyopathy, active myocarditis, constrictive pericarditis, cardiac tamponade, uncorrected more than moderate primary valve disease.
-
Primary pulmonary hypertension, chronic pulmonary embolism, severe pulmonary disease including COPD.
-
Any other condition judged by the investigator that could account for heart failure symptoms and signs (e.g., anaemia, hypothyroidism).
Medical conditions - infections/immunosuppression
- Clinical evidence of, or suspicion of, active infection at the discretion of the investigator.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Novo Nordisk Investigational Site | Alexander City | Alabama | United States | 35010 |
| 2 | Novo Nordisk Investigational Site | Fairhope | Alabama | United States | 36532 |
| 3 | Novo Nordisk Investigational Site | Huntsville | Alabama | United States | 35801 |
| 4 | Novo Nordisk Investigational Site | Beverly Hills | California | United States | 90211 |
| 5 | Novo Nordisk Investigational Site | La Mesa | California | United States | 91942 |
| 6 | Novo Nordisk Investigational Site | Loma Linda | California | United States | 92357 |
| 7 | Novo Nordisk Investigational Site | Mission Hills | California | United States | 91345 |
| 8 | Novo Nordisk Investigational Site | Northridge | California | United States | 91325 |
| 9 | Novo Nordisk Investigational Site | Palo Alto | California | United States | 94304 |
| 10 | Novo Nordisk Investigational Site | Torrance | California | United States | 90502 |
| 11 | Novo Nordisk Investigational Site | Bridgeport | Connecticut | United States | 06610 |
| 12 | Novo Nordisk Investigational Site | Crystal River | Florida | United States | 34429 |
| 13 | Novo Nordisk Investigational Site | Jacksonville | Florida | United States | 32204 |
| 14 | Novo Nordisk Investigational Site | Jacksonville | Florida | United States | 32258 |
| 15 | Novo Nordisk Investigational Site | Miami | Florida | United States | 33155 |
| 16 | Novo Nordisk Investigational Site | North Miami Beach | Florida | United States | 33169 |
| 17 | Novo Nordisk Investigational Site | Ocala | Florida | United States | 34471 |
| 18 | Novo Nordisk Investigational Site | Saint Augustine | Florida | United States | 32086 |
| 19 | Novo Nordisk Investigational Site | Wellington | Florida | United States | 33449 |
| 20 | Novo Nordisk Investigational Site | Atlanta | Georgia | United States | 30310 |
| 21 | Novo Nordisk Investigational Site | Johns Creek | Georgia | United States | 30024 |
| 22 | Novo Nordisk Investigational Site | Macon | Georgia | United States | 31201 |
| 23 | Novo Nordisk Investigational Site | Arlington Heights | Illinois | United States | 60005 |
| 24 | Novo Nordisk Investigational Site | Hazel Crest | Illinois | United States | 60429 |
| 25 | Novo Nordisk Investigational Site | Elkhart | Indiana | United States | 46514 |
| 26 | Novo Nordisk Investigational Site | Indianapolis | Indiana | United States | 46237 |
| 27 | Novo Nordisk Investigational Site | Lebanon | Indiana | United States | 46052 |
| 28 | Novo Nordisk Investigational Site | Munster | Indiana | United States | 46321 |
| 29 | Novo Nordisk Investigational Site | Richmond | Indiana | United States | 47374 |
| 30 | Novo Nordisk Investigational Site | Overland Park | Kansas | United States | 66211 |
| 31 | Novo Nordisk Investigational Site | Elizabethtown | Kentucky | United States | 42701 |
| 32 | Novo Nordisk Investigational Site | Lexington | Kentucky | United States | 40503 |
| 33 | Novo Nordisk Investigational Site | Louisville | Kentucky | United States | 40202 |
| 34 | Novo Nordisk Investigational Site | Louisville | Kentucky | United States | 40207 |
| 35 | Novo Nordisk Investigational Site | Hammond | Louisiana | United States | 70403 |
| 36 | Novo Nordisk Investigational Site | Baltimore | Maryland | United States | 21287 |
| 37 | Novo Nordisk Investigational Site | Oxon Hill | Maryland | United States | 20745 |
| 38 | Novo Nordisk Investigational Site | Towson | Maryland | United States | 21229 |
| 39 | Novo Nordisk Investigational Site | Haverhill | Massachusetts | United States | 01830 |
| 40 | Novo Nordisk Investigational Site | Detroit | Michigan | United States | 48202 |
| 41 | Novo Nordisk Investigational Site | Ypsilanti | Michigan | United States | 48197 |
| 42 | Novo Nordisk Investigational Site | Maplewood | Minnesota | United States | 55109 |
| 43 | Novo Nordisk Investigational Site | Minneapolis | Minnesota | United States | 55417 |
| 44 | Novo Nordisk Investigational Site | Tupelo | Mississippi | United States | 38801 |
| 45 | Novo Nordisk Investigational Site | Saint Louis | Missouri | United States | 63136 |
| 46 | Novo Nordisk Investigational Site | Newark | New Jersey | United States | 07102 |
| 47 | Novo Nordisk Investigational Site | Ridgewood | New Jersey | United States | 07450 |
| 48 | Novo Nordisk Investigational Site | Bronx | New York | United States | 10455 |
| 49 | Novo Nordisk Investigational Site | Buffalo | New York | United States | 14215 |
| 50 | Novo Nordisk Investigational Site | New York | New York | United States | 10021 |
| 51 | Novo Nordisk Investigational Site | New York | New York | United States | 10035 |
| 52 | Novo Nordisk Investigational Site | Saratoga Springs | New York | United States | 12866 |
| 53 | Novo Nordisk Investigational Site | Stony Brook | New York | United States | 11794 |
| 54 | Novo Nordisk Investigational Site | Durham | North Carolina | United States | 27710 |
| 55 | Novo Nordisk Investigational Site | Greensboro | North Carolina | United States | 27405 |
| 56 | Novo Nordisk Investigational Site | Lumberton | North Carolina | United States | 28358 |
| 57 | Novo Nordisk Investigational Site | Morehead City | North Carolina | United States | 28557 |
| 58 | Novo Nordisk Investigational Site | Marion | Ohio | United States | 43302 |
| 59 | Novo Nordisk Investigational Site | Lancaster | Pennsylvania | United States | 17602 |
| 60 | Novo Nordisk Investigational Site | Rapid City | South Dakota | United States | 57701 |
| 61 | Novo Nordisk Investigational Site | Jackson | Tennessee | United States | 38301 |
| 62 | Novo Nordisk Investigational Site | Amarillo | Texas | United States | 79109 |
| 63 | Novo Nordisk Investigational Site | Dallas | Texas | United States | 75235 |
| 64 | Novo Nordisk Investigational Site | Houston | Texas | United States | 77030 |
| 65 | Novo Nordisk Investigational Site | Houston | Texas | United States | 77070 |
| 66 | Novo Nordisk Investigational Site | Sherman | Texas | United States | 75092 |
| 67 | Novo Nordisk Investigational Site | Falls Church | Virginia | United States | 22042 |
| 68 | Novo Nordisk Investigational Site | Norfolk | Virginia | United States | 23504 |
| 69 | Novo Nordisk Investigational Site | Winchester | Virginia | United States | 22601-3834 |
| 70 | Novo Nordisk Investigational Site | Madison | Wisconsin | United States | 53705 |
| 71 | Novo Nordisk Investigational Site | Caba | Buenos Aires | Argentina | C1128 AAF |
| 72 | Novo Nordisk Investigational Site | Granadero Baigorria | Santa Fe | Argentina | 2152 |
| 73 | Novo Nordisk Investigational Site | Buenos Aires | Argentina | B1704ETD | |
| 74 | Novo Nordisk Investigational Site | Caba | Argentina | C1093AAS | |
| 75 | Novo Nordisk Investigational Site | Caba | Argentina | C1440CFD | |
| 76 | Novo Nordisk Investigational Site | Corrientes | Argentina | W3400AMZ | |
| 77 | Novo Nordisk Investigational Site | Mar del Plata | Argentina | B7600FZN | |
| 78 | Novo Nordisk Investigational Site | Mar del Plata | Argentina | B7600GNY | |
| 79 | Novo Nordisk Investigational Site | San Nicolás | Argentina | B2900 | |
| 80 | Novo Nordisk Investigational Site | Santa Fe | Argentina | 3000 | |
| 81 | Novo Nordisk Investigational Site | Braunau | Austria | A 5280 | |
| 82 | Novo Nordisk Investigational Site | Saint Stefan | Austria | 8511 | |
| 83 | Novo Nordisk Investigational Site | Wien | Austria | 1100 | |
| 84 | Novo Nordisk Investigational Site | Wien | Austria | A 1190 | |
| 85 | Novo Nordisk Investigational Site | Edegem | Belgium | 2650 | |
| 86 | Novo Nordisk Investigational Site | Genk | Belgium | 3600 | |
| 87 | Novo Nordisk Investigational Site | Kortrijk | Belgium | 8500 | |
| 88 | Novo Nordisk Investigational Site | Banja Luka | Bosnia and Herzegovina | 78000 | |
| 89 | Novo Nordisk Investigational Site | Sarajevo | Bosnia and Herzegovina | 71000 | |
| 90 | Novo Nordisk Investigational Site | Porto Alegre | Rio Grande Do Sul | Brazil | 90035-003 |
| 91 | Novo Nordisk Investigational Site | Campinas | Sao Paulo | Brazil | 13010-001 |
| 92 | Novo Nordisk Investigational Site | Campinas | Sao Paulo | Brazil | 13059-740 |
| 93 | Novo Nordisk Investigational Site | Campinas | Sao Paulo | Brazil | 13060-080 |
| 94 | Novo Nordisk Investigational Site | São José do Rio Preto | Sao Paulo | Brazil | 15090-000 |
| 95 | Novo Nordisk Investigational Site | Belo Horizonte/MG | Brazil | 30220-140 | |
| 96 | Novo Nordisk Investigational Site | Goiânia/GO | Brazil | 74605-020 | |
| 97 | Novo Nordisk Investigational Site | Porto Alegre/RS | Brazil | 90840-440 | |
| 98 | Novo Nordisk Investigational Site | Recife/PE | Brazil | 56517-630 | |
| 99 | Novo Nordisk Investigational Site | Ribeirão Preto/SP | Brazil | 14051-140 | |
| 100 | Novo Nordisk Investigational Site | Rio de Janeiro | Brazil | 22061-080 | |
| 101 | Novo Nordisk Investigational Site | Rio de Janeiro | Brazil | 22281-100 | |
| 102 | Novo Nordisk Investigational Site | São Paulo/SP | Brazil | 04040-001 | |
| 103 | Novo Nordisk Investigational Site | Burgas | Bulgaria | 8000 | |
| 104 | Novo Nordisk Investigational Site | Kozloduy | Bulgaria | 3320 | |
| 105 | Novo Nordisk Investigational Site | Lom | Bulgaria | 3600 | |
| 106 | Novo Nordisk Investigational Site | Panagyurishte | Bulgaria | 4500 | |
| 107 | Novo Nordisk Investigational Site | Pleven | Bulgaria | 5800 | |
| 108 | Novo Nordisk Investigational Site | Plovdiv | Bulgaria | 4002 | |
| 109 | Novo Nordisk Investigational Site | Sandanski | Bulgaria | 2800 | |
| 110 | Novo Nordisk Investigational Site | Sevlievo | Bulgaria | 5400 | |
| 111 | Novo Nordisk Investigational Site | Sofia | Bulgaria | 1202 | |
| 112 | Novo Nordisk Investigational Site | Sofia | Bulgaria | 1233 | |
| 113 | Novo Nordisk Investigational Site | Sofia | Bulgaria | 1431 | |
| 114 | Novo Nordisk Investigational Site | Sofia | Bulgaria | 1527 | |
| 115 | Novo Nordisk Investigational Site | Stara Zagora | Bulgaria | 6000 | |
| 116 | Novo Nordisk Investigational Site | Veliko Tarnovo | Bulgaria | 5000 | |
| 117 | Novo Nordisk Investigational Site | Calgary | Alberta | Canada | T2N 4Z6 |
| 118 | Novo Nordisk Investigational Site | New Westminster | British Columbia | Canada | V3L 3W7 |
| 119 | Novo Nordisk Investigational Site | North Vancouver | British Columbia | Canada | V7M 2H4 |
| 120 | Novo Nordisk Investigational Site | Surrey | British Columbia | Canada | V2V 0C6 |
| 121 | Novo Nordisk Investigational Site | Vancouver | British Columbia | Canada | V5Z1M9 |
| 122 | Novo Nordisk Investigational Site | Winnipeg | Manitoba | Canada | R2H 2HA6 |
| 123 | Novo Nordisk Investigational Site | Moncton | New Brunswick | Canada | E1G 1A7 |
| 124 | Novo Nordisk Investigational Site | Cambridge | Ontario | Canada | N1R 6V6 |
| 125 | Novo Nordisk Investigational Site | Cambridge | Ontario | Canada | N1R7R1 |
| 126 | Novo Nordisk Investigational Site | Guelph | Ontario | Canada | N1H 1B1 |
| 127 | Novo Nordisk Investigational Site | London | Ontario | Canada | N6A 4V2 |
| 128 | Novo Nordisk Investigational Site | Newmarket | Ontario | Canada | L3Y 2P6 |
| 129 | Novo Nordisk Investigational Site | North York | Ontario | Canada | M6B 3H7 |
| 130 | Novo Nordisk Investigational Site | Peterborough | Ontario | Canada | K9J 0B2 |
| 131 | Novo Nordisk Investigational Site | Toronto | Ontario | Canada | M6G 1M2 |
| 132 | Novo Nordisk Investigational Site | Winchester | Ontario | Canada | K0C 2K0 |
| 133 | Novo Nordisk Investigational Site | Brossard | Quebec | Canada | J4Z-2K9 |
| 134 | Novo Nordisk Investigational Site | Montréal | Quebec | Canada | H2X 0C1 |
| 135 | Novo Nordisk Investigational Site | Sherbrooke | Quebec | Canada | J1G 2E8 |
| 136 | Novo Nordisk Investigational Site | Terrebonne | Quebec | Canada | J6V 2H2 |
| 137 | Novo Nordisk Investigational Site | Trois-Rivières | Quebec | Canada | G9A 4P3 |
| 138 | Novo Nordisk Investigational Site | Beijing | Beijing | China | 100029 |
| 139 | Novo Nordisk Investigational Site | Manizales | Caldas | Colombia | 170003 |
| 140 | Novo Nordisk Investigational Site | Bucaramanga-piedecuesta, Valle Del Menzuli - Santander | Santander | Colombia | 681012 |
| 141 | Novo Nordisk Investigational Site | Barranquilla | Colombia | 080001 | |
| 142 | Novo Nordisk Investigational Site | Barranquilla | Colombia | 080020 | |
| 143 | Novo Nordisk Investigational Site | Barranquilla | Colombia | 80020 | |
| 144 | Novo Nordisk Investigational Site | Medellin | Colombia | 050015 | |
| 145 | Novo Nordisk Investigational Site | Medellin | Colombia | 050021 | |
| 146 | Novo Nordisk Investigational Site | Medellin | Colombia | 050030 | |
| 147 | Novo Nordisk Investigational Site | Medellin | Colombia | 050034 | |
| 148 | Novo Nordisk Investigational Site | Soledad | Colombia | 83001 | |
| 149 | Novo Nordisk Investigational Site | Cakovec | Croatia | 40000 | |
| 150 | Novo Nordisk Investigational Site | Krapinske Toplice | Croatia | 49217 | |
| 151 | Novo Nordisk Investigational Site | Osijek | Croatia | 31 000 | |
| 152 | Novo Nordisk Investigational Site | Rijeka | Croatia | 51000 | |
| 153 | Novo Nordisk Investigational Site | Split | Croatia | 21 000 | |
| 154 | Novo Nordisk Investigational Site | Zagreb | Croatia | 10 000 | |
| 155 | Novo Nordisk Investigational Site | Hradec Kralove | Czechia | 50005 | |
| 156 | Novo Nordisk Investigational Site | Liberec | Czechia | 460 02 | |
| 157 | Novo Nordisk Investigational Site | Plzen -Bory | Czechia | 305 99 | |
| 158 | Novo Nordisk Investigational Site | Policka | Czechia | 572 01 | |
| 159 | Novo Nordisk Investigational Site | Praha 1 | Czechia | 110 00 | |
| 160 | Novo Nordisk Investigational Site | Praha 2 | Czechia | 120 00 | |
| 161 | Novo Nordisk Investigational Site | Slany | Czechia | 274 01 | |
| 162 | Novo Nordisk Investigational Site | Tabor | Czechia | 39003 | |
| 163 | Novo Nordisk Investigational Site | Trutnov | Czechia | 541 01 | |
| 164 | Novo Nordisk Investigational Site | Uherske Hradiste | Czechia | 68601 | |
| 165 | Novo Nordisk Investigational Site | Aarhus N | Denmark | 8200 | |
| 166 | Novo Nordisk Investigational Site | Copenhagen | Denmark | 2400 | |
| 167 | Novo Nordisk Investigational Site | Hellerup | Denmark | 2900 | |
| 168 | Novo Nordisk Investigational Site | Roskilde | Denmark | 4000 | |
| 169 | Novo Nordisk Investigational Site | Svendborg | Denmark | 5700 | |
| 170 | Novo Nordisk Investigational Site | Tallinn | Estonia | 10138 | |
| 171 | Novo Nordisk Investigational Site | Tallinn | Estonia | 13419 | |
| 172 | Novo Nordisk Investigational Site | Tartu | Estonia | 50406 | |
| 173 | Novo Nordisk Investigational Site | Jyväskylä | Finland | 40620 | |
| 174 | Novo Nordisk Investigational Site | Kuopio | Finland | 70100 | |
| 175 | Novo Nordisk Investigational Site | Seinäjoki | Finland | 60220 | |
| 176 | Novo Nordisk Investigational Site | Tampere | Finland | 33520 | |
| 177 | Novo Nordisk Investigational Site | Turku | Finland | 20520 | |
| 178 | Novo Nordisk Investigational Site | La Tronche | France | 38700 | |
| 179 | Novo Nordisk Investigational Site | Montpellier | France | 34295 | |
| 180 | Novo Nordisk Investigational Site | Paris | France | 75010 | |
| 181 | Novo Nordisk Investigational Site | Paris | France | 75013 | |
| 182 | Novo Nordisk Investigational Site | Poitiers | France | 86000 | |
| 183 | Novo Nordisk Investigational Site | Toulouse | France | 31059 | |
| 184 | Novo Nordisk Investigational Site | Aachen | Germany | 52074 | |
| 185 | Novo Nordisk Investigational Site | Berlin | Germany | 10787 | |
| 186 | Novo Nordisk Investigational Site | Berlin | Germany | 13353 | |
| 187 | Novo Nordisk Investigational Site | Bremen | Germany | 28277 | |
| 188 | Novo Nordisk Investigational Site | Dortmund | Germany | 44137 | |
| 189 | Novo Nordisk Investigational Site | Dresden | Germany | 01277 | |
| 190 | Novo Nordisk Investigational Site | Dresden | Germany | 01307 | |
| 191 | Novo Nordisk Investigational Site | Elsterwerda | Germany | 04910 | |
| 192 | Novo Nordisk Investigational Site | Frankfurt | Germany | 60389 | |
| 193 | Novo Nordisk Investigational Site | Freiburg | Germany | 79106 | |
| 194 | Novo Nordisk Investigational Site | Giessen | Germany | 35392 | |
| 195 | Novo Nordisk Investigational Site | Göttingen | Germany | 37075 | |
| 196 | Novo Nordisk Investigational Site | Hamburg | Germany | 20251 | |
| 197 | Novo Nordisk Investigational Site | Hassloch | Germany | 67454 | |
| 198 | Novo Nordisk Investigational Site | Homburg | Germany | 66421 | |
| 199 | Novo Nordisk Investigational Site | Jena | Germany | 07747 | |
| 200 | Novo Nordisk Investigational Site | Kaiserslautern | Germany | 67655 | |
| 201 | Novo Nordisk Investigational Site | Leipzig | Germany | 04103 | |
| 202 | Novo Nordisk Investigational Site | Mannheim | Germany | 68165 | |
| 203 | Novo Nordisk Investigational Site | München | Germany | 81377 | |
| 204 | Novo Nordisk Investigational Site | Papenburg | Germany | 26871 | |
| 205 | Novo Nordisk Investigational Site | Wermsdorf | Germany | 04779 | |
| 206 | Novo Nordisk Investigational Site | Würzburg | Germany | 97078 | |
| 207 | Novo Nordisk Investigational Site | Heraklion | Crete | Greece | GR-71500 |
| 208 | Novo Nordisk Investigational Site | Athens | Greece | 11527 | |
| 209 | Novo Nordisk Investigational Site | Athens | Greece | GR-11527 | |
| 210 | Novo Nordisk Investigational Site | Athens | Greece | GR-14233 | |
| 211 | Novo Nordisk Investigational Site | Athens | Greece | GR-15123 | |
| 212 | Novo Nordisk Investigational Site | Athens | Greece | GR-15125 | |
| 213 | Novo Nordisk Investigational Site | Athens | Greece | GR11528 | |
| 214 | Novo Nordisk Investigational Site | Chaidari, Athens | Greece | GR-12462 | |
| 215 | Novo Nordisk Investigational Site | Chios | Greece | GR82100 | |
| 216 | Novo Nordisk Investigational Site | Larissa | Greece | GR-41110 | |
| 217 | Novo Nordisk Investigational Site | Pylea, Thessaloniki | Greece | GR-57001 | |
| 218 | Novo Nordisk Investigational Site | Rio Patras | Greece | GR26504 | |
| 219 | Novo Nordisk Investigational Site | Thessaloniki | Greece | 54635 | |
| 220 | Novo Nordisk Investigational Site | Thessaloniki | Greece | 54636 | |
| 221 | Novo Nordisk Investigational Site | Thessaloniki | Greece | GR54642 | |
| 222 | Novo Nordisk Investigational Site | Baja | Hungary | 6500 | |
| 223 | Novo Nordisk Investigational Site | Budapest | Hungary | 1096 | |
| 224 | Novo Nordisk Investigational Site | Budapest | Hungary | 1122 | |
| 225 | Novo Nordisk Investigational Site | Budapest | Hungary | 1204 | |
| 226 | Novo Nordisk Investigational Site | Békéscsaba | Hungary | 5600 | |
| 227 | Novo Nordisk Investigational Site | Kaposvár | Hungary | 7400 | |
| 228 | Novo Nordisk Investigational Site | Komárom | Hungary | 2921 | |
| 229 | Novo Nordisk Investigational Site | Orosháza | Hungary | 5900 | |
| 230 | Novo Nordisk Investigational Site | Pécs | Hungary | 7624 | |
| 231 | Novo Nordisk Investigational Site | Szeged | Hungary | 6725 | |
| 232 | Novo Nordisk Investigational Site | Zalaegerszeg | Hungary | 8900 | |
| 233 | Novo Nordisk Investigational Site | Vijayawada | Andhra Pradesh | India | 520008 |
| 234 | Novo Nordisk Investigational Site | Ahmedabad | Gujarat | India | 380060 |
| 235 | Novo Nordisk Investigational Site | Ahmedabad | Gujarat | India | 38006 |
| 236 | Novo Nordisk Investigational Site | Surat | Gujarat | India | 395001 |
| 237 | Novo Nordisk Investigational Site | Vadodara | Gujarat | India | 390022 |
| 238 | Novo Nordisk Investigational Site | Gurugram | Haryana | India | 122001 |
| 239 | Novo Nordisk Investigational Site | Bangalore | Karnataka | India | 560017 |
| 240 | Novo Nordisk Investigational Site | Cochin | Kerala | India | 682041 |
| 241 | Novo Nordisk Investigational Site | Kochi | Kerala | India | 682018 |
| 242 | Novo Nordisk Investigational Site | Kozhikode | Kerala | India | 673008 |
| 243 | Novo Nordisk Investigational Site | Mumbai | Maharashtra | India | 400012 |
| 244 | Novo Nordisk Investigational Site | Nagpur | Maharashtra | India | 440003 |
| 245 | Novo Nordisk Investigational Site | Nagpur | Maharashtra | India | 440010 |
| 246 | Novo Nordisk Investigational Site | Pune | Maharashtra | India | 411001 |
| 247 | Novo Nordisk Investigational Site | Pune | Maharashtra | India | 411011 |
| 248 | Novo Nordisk Investigational Site | New Dehli | New Delhi | India | 110029 |
| 249 | Novo Nordisk Investigational Site | Jaipur | Rajasthan | India | 302001 |
| 250 | Novo Nordisk Investigational Site | Hyderbad | Telengana | India | 500 012 |
| 251 | Novo Nordisk Investigational Site | Dehradun | Uttarakhand | India | 248001 |
| 252 | Novo Nordisk Investigational Site | Aligarh | India | 202002 | |
| 253 | Novo Nordisk Investigational Site | Jodhpur | India | 342005 | |
| 254 | Novo Nordisk Investigational Site | Lucknow | India | 226003 | |
| 255 | Novo Nordisk Investigational Site | New Delhi | India | 110002 | |
| 256 | Novo Nordisk Investigational Site | New Delhi | India | 110025 | |
| 257 | Novo Nordisk Investigational Site | New Delhi | India | 110060 | |
| 258 | Novo Nordisk Investigational Site | New Delhi | India | 110075 | |
| 259 | Novo Nordisk Investigational Site | Palakkad | India | 678013 | |
| 260 | Novo Nordisk Investigational Site | Cork | Ireland | T12 DC4A | |
| 261 | Novo Nordisk Investigational Site | Dublin | Ireland | A96 D628 | |
| 262 | Novo Nordisk Investigational Site | Dublin | Ireland | D07 KX5K | |
| 263 | Novo Nordisk Investigational Site | Dublin | Ireland | D07KWR1 | |
| 264 | Novo Nordisk Investigational Site | Dublin | Ireland | D08 A978 | |
| 265 | Novo Nordisk Investigational Site | Haifa | Israel | 3109601 | |
| 266 | Novo Nordisk Investigational Site | Jerusalem | Israel | 91120 | |
| 267 | Novo Nordisk Investigational Site | Petah-Tikva | Israel | 49100 | |
| 268 | Novo Nordisk Investigational Site | Tel Aviv | Israel | 6423906 | |
| 269 | Novo Nordisk Investigational Site | Tel Hashomer | Israel | 5265601 | |
| 270 | Novo Nordisk Investigational Site | Zrifin | Israel | 70300 | |
| 271 | Novo Nordisk Investigational Site | Benevento | Italy | 82100 | |
| 272 | Novo Nordisk Investigational Site | Bergamo | Italy | 24127 | |
| 273 | Novo Nordisk Investigational Site | Brescia | Italy | 25123 | |
| 274 | Novo Nordisk Investigational Site | Casale Monferrato | Italy | 15033 | |
| 275 | Novo Nordisk Investigational Site | Caserta | Italy | 81100 | |
| 276 | Novo Nordisk Investigational Site | Catanzaro | Italy | 88100 | |
| 277 | Novo Nordisk Investigational Site | Cona (Ferrara) | Italy | 44124 | |
| 278 | Novo Nordisk Investigational Site | Foggia | Italy | 71122 | |
| 279 | Novo Nordisk Investigational Site | Genova | Italy | 16132 | |
| 280 | Novo Nordisk Investigational Site | Napoli | Italy | 80131 | |
| 281 | Novo Nordisk Investigational Site | Novara | Italy | 28100 | |
| 282 | Novo Nordisk Investigational Site | Pavia | Italy | 27100 | |
| 283 | Novo Nordisk Investigational Site | Perugia | Italy | 06129 | |
| 284 | Novo Nordisk Investigational Site | Pisa | Italy | 56126 | |
| 285 | Novo Nordisk Investigational Site | Rivoli | Italy | 10098 | |
| 286 | Novo Nordisk Investigational Site | Roma | Italy | 00135 | |
| 287 | Novo Nordisk Investigational Site | Siena | Italy | 53100 | |
| 288 | Novo Nordisk Investigational Site | Torino | Italy | 10128 | |
| 289 | Novo Nordisk Investigational Site | Trieste | Italy | 34128 | |
| 290 | Novo Nordisk Investigational Site | Verona | Italy | 37126 | |
| 291 | Novo Nordisk Investigational Site | Riga | Latvia | LV-1001 | |
| 292 | Novo Nordisk Investigational Site | Riga | Latvia | LV-1002 | |
| 293 | Novo Nordisk Investigational Site | Riga | Latvia | LV-1023 | |
| 294 | Novo Nordisk Investigational Site | Riga | Latvia | LV1011 | |
| 295 | Novo Nordisk Investigational Site | Riga | Latvia | LV1038 | |
| 296 | Novo Nordisk Investigational Site | Kaunas | Lithuania | 49449 | |
| 297 | Novo Nordisk Investigational Site | Kaunas | Lithuania | LT-49387 | |
| 298 | Novo Nordisk Investigational Site | Siauliai | Lithuania | 76231 | |
| 299 | Novo Nordisk Investigational Site | Vilnius | Lithuania | LT-08406 | |
| 300 | Novo Nordisk Investigational Site | Cheras | Kuala Lumpur | Malaysia | 56000 |
| 301 | Novo Nordisk Investigational Site | Sungai Buloh | Selangor | Malaysia | 47000 |
| 302 | Novo Nordisk Investigational Site | Alor Setar | Malaysia | 05460 | |
| 303 | Novo Nordisk Investigational Site | Kota Bharu, Kelantan | Malaysia | 16150 | |
| 304 | Novo Nordisk Investigational Site | Kota Samarahan | Malaysia | 94300 | |
| 305 | Novo Nordisk Investigational Site | Kuala Lumpur | Malaysia | 59100 | |
| 306 | Novo Nordisk Investigational Site | Kuantan | Malaysia | 25100 | |
| 307 | Novo Nordisk Investigational Site | Aguascalientes | Ags | Mexico | 20230 |
| 308 | Novo Nordisk Investigational Site | Guadalajara | Jalisco | Mexico | 44130 |
| 309 | Novo Nordisk Investigational Site | Ciudad de Mexico | México, D.F. | Mexico | 14080 |
| 310 | Novo Nordisk Investigational Site | Monterrey | Nuevo Leon | Mexico | 64060 |
| 311 | Novo Nordisk Investigational Site | Monterrey | Nuevo Leon | Mexico | 64718 |
| 312 | Novo Nordisk Investigational Site | Monterrey | Nuevo León | Mexico | 64020 |
| 313 | Novo Nordisk Investigational Site | Santiago De Querétaro, Qro. | Querétaro | Mexico | 76000 |
| 314 | Novo Nordisk Investigational Site | San Luis Potosí | San Luis Potosi | Mexico | 78200 |
| 315 | Novo Nordisk Investigational Site | Culiacán | Sinaloa | Mexico | 80230 |
| 316 | Novo Nordisk Investigational Site | Xalapa | Veracruz | Mexico | 91193 |
| 317 | Novo Nordisk Investigational Site | Den Haag | Netherlands | 2545AA | |
| 318 | Novo Nordisk Investigational Site | Deventer | Netherlands | 7416 SE | |
| 319 | Novo Nordisk Investigational Site | Dordrecht | Netherlands | 3318 AT | |
| 320 | Novo Nordisk Investigational Site | Emmen | Netherlands | 7824 AA | |
| 321 | Novo Nordisk Investigational Site | Enschede | Netherlands | 7512 KZ | |
| 322 | Novo Nordisk Investigational Site | Groningen | Netherlands | 9713 GZ | |
| 323 | Novo Nordisk Investigational Site | Heerlen | Netherlands | 6419 PC | |
| 324 | Novo Nordisk Investigational Site | Maastricht | Netherlands | 6229 HX | |
| 325 | Novo Nordisk Investigational Site | Nijmegen | Netherlands | 6525 GA | |
| 326 | Novo Nordisk Investigational Site | Rotterdam | Netherlands | 3015 GD | |
| 327 | Novo Nordisk Investigational Site | Skopje | North Macedonia | 1000 | |
| 328 | Novo Nordisk Investigational Site | Bergen | Norway | 5021 | |
| 329 | Novo Nordisk Investigational Site | Lørenskog | Norway | 1478 | |
| 330 | Novo Nordisk Investigational Site | Oslo | Norway | 0372 | |
| 331 | Novo Nordisk Investigational Site | Oslo | Norway | 0450 | |
| 332 | Novo Nordisk Investigational Site | Stavanger | Norway | NO-4011 | |
| 333 | Novo Nordisk Investigational Site | Belchatow | Poland | 97-400 | |
| 334 | Novo Nordisk Investigational Site | Bialystok | Poland | 15-111 | |
| 335 | Novo Nordisk Investigational Site | Bialystok | Poland | 15-276 | |
| 336 | Novo Nordisk Investigational Site | Chrzanów | Poland | 32-500 | |
| 337 | Novo Nordisk Investigational Site | Cracow | Poland | 30-701 | |
| 338 | Novo Nordisk Investigational Site | Dąbrowa Górnicza | Poland | 41-300 | |
| 339 | Novo Nordisk Investigational Site | Gdynia | Poland | 81-157 | |
| 340 | Novo Nordisk Investigational Site | Grodzisk Mazowiecki | Poland | 05-825 | |
| 341 | Novo Nordisk Investigational Site | Katowice | Poland | 40-635 | |
| 342 | Novo Nordisk Investigational Site | Krakow | Poland | 30-082 | |
| 343 | Novo Nordisk Investigational Site | Krakow | Poland | 31-271 | |
| 344 | Novo Nordisk Investigational Site | Lodz | Poland | 90-549 | |
| 345 | Novo Nordisk Investigational Site | Lodz | Poland | 91-347 | |
| 346 | Novo Nordisk Investigational Site | Lodz | Poland | 93-338 | |
| 347 | Novo Nordisk Investigational Site | Przemysl | Poland | 37-700 | |
| 348 | Novo Nordisk Investigational Site | Ruda Slaska | Poland | 41-710 | |
| 349 | Novo Nordisk Investigational Site | Torun | Poland | 87-100 | |
| 350 | Novo Nordisk Investigational Site | Tychy | Poland | 43-100 | |
| 351 | Novo Nordisk Investigational Site | Warszawa | Poland | 00-416 | |
| 352 | Novo Nordisk Investigational Site | Warszawa | Poland | 04-141 | |
| 353 | Novo Nordisk Investigational Site | Wroclaw | Poland | 50-556 | |
| 354 | Novo Nordisk Investigational Site | Wroclaw | Poland | 51-134 | |
| 355 | Novo Nordisk Investigational Site | Wroclaw | Poland | 53-114 | |
| 356 | Novo Nordisk Investigational Site | Włocławek | Poland | 87-800 | |
| 357 | Novo Nordisk Investigational Site | Zabrze | Poland | 41-800 | |
| 358 | Novo Nordisk Investigational Site | Katowice | Śląskie | Poland | 40-648 |
| 359 | Novo Nordisk Investigational Site | Guilhufe - Penafiel | Portugal | 4560-136 | |
| 360 | Novo Nordisk Investigational Site | Lisboa | Portugal | 1500-650 | |
| 361 | Novo Nordisk Investigational Site | Lisboa | Portugal | 1649-035 | |
| 362 | Novo Nordisk Investigational Site | Lisbon | Portugal | 1449-005 | |
| 363 | Novo Nordisk Investigational Site | Porto | Portugal | 4099-001 | |
| 364 | Novo Nordisk Investigational Site | Setubal | Portugal | 2910-446 | |
| 365 | Novo Nordisk Investigational Site | Bucuresti | Buzau | Romania | 120133 |
| 366 | Novo Nordisk Investigational Site | Tirgu Mures | Targu Mures | Romania | 540143 |
| 367 | Novo Nordisk Investigational Site | Baia Mare | Romania | 430222 | |
| 368 | Novo Nordisk Investigational Site | Braila | Romania | 810325 | |
| 369 | Novo Nordisk Investigational Site | Brasov | Romania | 500283 | |
| 370 | Novo Nordisk Investigational Site | Bucharest | Romania | 021875 | |
| 371 | Novo Nordisk Investigational Site | Bucuresti | Romania | 011057 | |
| 372 | Novo Nordisk Investigational Site | Bucuresti | Romania | 011461 | |
| 373 | Novo Nordisk Investigational Site | Bucuresti | Romania | 012292 | |
| 374 | Novo Nordisk Investigational Site | Bucuresti | Romania | 014142 | |
| 375 | Novo Nordisk Investigational Site | Bucuresti | Romania | 022762 | |
| 376 | Novo Nordisk Investigational Site | Bucuresti | Romania | 050098 | |
| 377 | Novo Nordisk Investigational Site | Constanta | Romania | 900591 | |
| 378 | Novo Nordisk Investigational Site | Craiova | Romania | 200513 | |
| 379 | Novo Nordisk Investigational Site | Galati | Romania | 800291 | |
| 380 | Novo Nordisk Investigational Site | Iasi | Romania | 700503 | |
| 381 | Novo Nordisk Investigational Site | Iasi | Romania | 700547 | |
| 382 | Novo Nordisk Investigational Site | Iasi | Romania | 700732 | |
| 383 | Novo Nordisk Investigational Site | Pascani | Romania | 700502 | |
| 384 | Novo Nordisk Investigational Site | Pitesti | Romania | 110424 | |
| 385 | Novo Nordisk Investigational Site | Targu Mures | Romania | 540136 | |
| 386 | Novo Nordisk Investigational Site | Timisoara | Romania | 300310 | |
| 387 | Novo Nordisk Investigational Site | Timișoara | Romania | 300254 | |
| 388 | Novo Nordisk Investigational Site | Belgrade | Serbia | 11000 | |
| 389 | Novo Nordisk Investigational Site | Belgrade | Serbia | 11080 | |
| 390 | Novo Nordisk Investigational Site | Singapore | Singapore | 119074 | |
| 391 | Novo Nordisk Investigational Site | Singapore | Singapore | 169609 | |
| 392 | Novo Nordisk Investigational Site | Singapore | Singapore | 529889 | |
| 393 | Novo Nordisk Investigational Site | Singapore | Singapore | 544886 | |
| 394 | Novo Nordisk Investigational Site | Brezno | Banskobystricky Kraj | Slovakia | 977 01 |
| 395 | Novo Nordisk Investigational Site | Svidnik | Presovsky Kraj | Slovakia | 089 01 |
| 396 | Novo Nordisk Investigational Site | Bratislava | Slovakia | 84108 | |
| 397 | Novo Nordisk Investigational Site | Kosice | Slovakia | 040 22 | |
| 398 | Novo Nordisk Investigational Site | Nitra | Slovakia | 949 01 | |
| 399 | Novo Nordisk Investigational Site | Trnava | Slovakia | 917 02 | |
| 400 | Novo Nordisk Investigational Site | Zilina | Slovakia | 010 01 | |
| 401 | Novo Nordisk Investigational Site | Celje | Slovenia | SI-3000 | |
| 402 | Novo Nordisk Investigational Site | Ljubljana | Slovenia | SI-1000 | |
| 403 | Novo Nordisk Investigational Site | Maribor | Slovenia | SI-2000 | |
| 404 | Novo Nordisk Investigational Site | Bloemfontein | Free State | South Africa | 9301 |
| 405 | Novo Nordisk Investigational Site | Johannesburg | Gauteng | South Africa | 2013 |
| 406 | Novo Nordisk Investigational Site | Johannesburg | Gauteng | South Africa | 2193 |
| 407 | Novo Nordisk Investigational Site | Lenasia | Gauteng | South Africa | 1827 |
| 408 | Novo Nordisk Investigational Site | Pretoria | Gauteng | South Africa | 0157 |
| 409 | Novo Nordisk Investigational Site | Cape Town | Western Cape | South Africa | 7500 |
| 410 | Novo Nordisk Investigational Site | Cape Town | Western Cape | South Africa | 7935 |
| 411 | Novo Nordisk Investigational Site | Mossel Bay | Western Cape | South Africa | 6506 |
| 412 | Novo Nordisk Investigational Site | Badalona | Barcelona | Spain | 08916 |
| 413 | Novo Nordisk Investigational Site | Hospitalet de Llobregat | Spain | 08907 | |
| 414 | Novo Nordisk Investigational Site | Las Palmas de Gran Canaria | Spain | 35019 | |
| 415 | Novo Nordisk Investigational Site | Madrid | Spain | 28034 | |
| 416 | Novo Nordisk Investigational Site | Madrid | Spain | 28040 | |
| 417 | Novo Nordisk Investigational Site | Madrid | Spain | 28222 | |
| 418 | Novo Nordisk Investigational Site | Sevilla | Spain | 41003 | |
| 419 | Novo Nordisk Investigational Site | Bangkok | Thailand | 10300 | |
| 420 | Novo Nordisk Investigational Site | Bangkok | Thailand | 10330 | |
| 421 | Novo Nordisk Investigational Site | Chichester | West Sussex | United Kingdom | PO19 6SE |
Sponsors and Collaborators
- Novo Nordisk A/S
Investigators
- Study Director: Clinical Transparency (dept. 2834), Novo Nordisk A/S
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
Novo Nordisk A/S
ClinicalTrials.gov Identifier:
NCT05636176
Other Study ID Numbers:
- EX6018-4915
- U1111-1280-0810
- 022-501939-16-00
First Posted:
Dec 5, 2022
Last Update Posted:
Dec 28, 2022
Last Verified:
Dec 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
Yes
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms: